BEAT Stock HeartBeam, Inc.
US · NasdaqCMLast in our picks 2026-10-20 — not in the current list; analysis below is from that screen
Novel cardiac-monitoring technology offers substantial upside if commercialization milestones are achieved.
Signal breakdown
- ▸Consensus target implies substantial upside, but liquidity and execution risks are high.
- ▾Below 50-day MA (-9.96%)
- ▾Near 52-week low (1.6% of range)
Is BEAT a buy right now?
Trend: BEAT is trading below the 50-day average (-10.68%), RSI 45 — neutral momentum, with a 3-month return of -25.14%.
Valuation & quality: HeartBeam, Inc. trades on forward P/E -0.8, price-to-book 2.82; fundamentals show net margin 0.0%, return on equity -328.4%.
Analyst consensus: 2 analysts have a mean 12-month price target of $3.50 (+755.3% vs the last close; range $2.00 – $5.00), consensus rating “none”.
Our screen: WATCH (score 0) — Novel cardiac-monitoring technology offers substantial upside if commercialization milestones are achieved.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -19.20% | -29.50% | +2.30% | -14.80% | -33.30% | -6.00% | -21.30% | +5.40% |
Fundamentals
Analyst price target
Technical signals
About HeartBeam, Inc.
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility.
Sector: Healthcare · Industry: Health Information Services · United States · 16 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.